FZ-P001 sodium

FZ-P001 sodium (FZ-P001 Sodium for Injection) is an investigational photosensitizer developed by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical using its proprietary photodynamic technology platform. Administered via parenteral injection, the drug is primarily being developed for the intraoperative visualization of malignant lesions. In December 2023, a Phase II clinical trial application was accepted in China for its use in patients with known or suspected lung cancer to assist in surgical visualization. Additionally, company pipeline information indicates that FZ-P001 is being explored for the management of known or suspected infections, potentially utilizing photodynamic properties for diagnostic or antimicrobial applications. While the specific active ingredient and molecular target have not been publicly disclosed, it is part of a platform that includes other aminolevulinic acid-based products.

Other names

注射用FZ-P001钠FZ-P001 Sodium for InjectionFZ-P-001 Sodium for InjectionFZ-P 001 Sodium for Injection